Lactation inhibition by the dopamine agonist CV 205–502

Summary. In an open pilot study with a parallel group design 30 bottle feeding women were randomly assigned in a two to one ratio to receive either the new dopamine agonist CV 205–502 or bromocriptine for lactation inhibition. Ten women who intended to breast feed served as normal controls. All treated women reached prepregnant prolactin levels within 72 h with once‐daily 0.075 mg of CV 205–502 or twice‐daily 2.5 mg of bromocriptine, at starting doses of 0.05 mg and 2.5 mg respectively. Fifteen of the 20 women treated with CV 205–502 reported breast symptoms, 50% occurring on days 3 and 4 of treatment. Three of the 10 women treated with bromocriptine had breast symptoms between days 2 and 28. Overall efficacy and tolerance in the two groups was very good. Side effects did not differ between the groups, with the exception of pulse rate in the standing position, which was significantly higher in the bromocriptine treated group than in either the CV 205–502 group (P = 0.02) or the breast feeding group (P < 0.01). The coagulation tests (fibrinogen, AT III, PTT and APTT) showed no significant differences between the three groups.

[1]  R. Rolland,et al.  The effectiveness, safety, and tolerability of CV 205-502 in hyperprolactinemic women: a 12-month study. , 1989, Fertility and sterility.

[2]  R. Sokol,et al.  Bromocriptine Mesylate for Lactation Suppression: A Risk for Postpartum Hypertension? , 1989, Obstetrics and gynecology.

[3]  I. Lancranjan,et al.  Return of gonadotropic function in postpartum women during bromocriptine treatment. , 1989, Fertility and sterility.

[4]  L. Wide,et al.  LONG‐TERM TREATMENT WITH A NEW NON‐ERGOT LONG‐ACTING DOPAMINE AGONIST, CV 205‐502, IN WOMEN WITH HYPERPROLACTINAEMIA , 1988, Clinical endocrinology.

[5]  R. Rolland,et al.  Endocrine effects of CV 205-502, a new dopamine agonist, in hyperprolactinemic women. , 1988, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[6]  L. Wide,et al.  CV 205‐502: A NEW LONG‐ACTING DRUG FOR INHIBITION OF PROLACTIN HYPERSECRETION , 1987, Clinical endocrinology.

[7]  W. Tenhove,et al.  Acute myocardial infarction in the puerperium in patients receiving bromocriptine. , 1986, American journal of obstetrics and gynecology.

[8]  I. Pak,et al.  Puerperal hypertension, stroke, and seizures after suppression of lactation with bromocriptine. , 1985, Obstetrics and gynecology.

[9]  T. Petcher,et al.  Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine. , 1985, Journal of medicinal chemistry.

[10]  R. Rolland,et al.  THE DYNAMICS OF PROLACTIN SECRETION DURING THE PUERPERIUM IN WOMEN , 1981, Clinical endocrinology.

[11]  R. Leke,et al.  Bromocriptine Mesylate for Prevention of Postpartum Lactation , 1981, Obstetrics and gynecology.

[12]  C. Bacon,et al.  Mothers' attitudes in infant feeding at Newcastle General Hospital in summer 1975. , 1976, British medical journal.

[13]  D. Smith,et al.  Further decline of breast-feeding. , 1976, British medical journal.

[14]  R. Rolland,et al.  A new approach to the inhibition of puerperal lactation. , 1974, The Journal of obstetrics and gynaecology of the British Commonwealth.

[15]  R. Rolland,et al.  A NEW APPROACH TO THE INHIBITION OF PUERPERAL LACTATION , 1973 .

[16]  P. M. Lutterbeck,et al.  Suppression of Puerperal Lactation with an Ergot Alkaloid: A Double-blind Study , 1972, British medical journal.

[17]  R. Rolland.  Use of Dopamine Agonists for Inhibition of Lactation , 1986 .

[18]  Postpartum hypertension, seizures, strokes reported with bromocriptine. , 1984, FDA drug bulletin.

[19]  R. Rolland,et al.  Inhibition of puerperal lactation by bromocriptine. , 1978, Acta endocrinologica. Supplementum.

[20]  A. Black,et al.  Lactation and reproduction. , 1975, Bulletin of the World Health Organization.